IART 51.49 Integra Lifesciences Holdings Corp $IAR
Post# of 32
Posted On: 11/03/2014 11:51:30 PM
IART 51.49 Integra Lifesciences Holdings Corp $IART Hit a 52 week high of 51.76 Closing the day 11/03/14 at 51.49 +0.38 +0.74% With a day low of 50.82 and a total volume of 244,047.
IART Recent Posts: http://investorshangout.com/Integra-Lifescien...ART-54399/
IART Integra Lifesciences Holdings Corp Recent Headline News
Integra LifeSciences Announces Strategic Portfolio Alignment and Plans to Create Stand-Alone Spine Business as a Separate Public Company
GlobeNewswire - Mon Nov 03, 5:28PM CST
-- Plans to Spin Off Spine Business to Create SeaSpine, a New Publicly Traded Company, By Means of Tax-Free Distribution to Integra Shareholders
IART: 51.49 (+0.38)
Integra LifeSciences Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 03, 5:28PM CST
Revenue Increased 7.7% to $229.7 Million
IART: 51.49 (+0.38)
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020
M2 - Mon Nov 03, 10:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/w3lrfq/germany_tissue) has announced the addition of the "Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Germany Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Germany 4 Overview of Key Companies in Germany, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned - Organogenesis, Inc. - Molnlycke Health Care AB - Smith & Nephew Plc - BSN medical GmbH - MedSkin Solutions Dr. Suwelack AG - Kinetic Concepts, Inc. - Covidien plc - Integra LifeSciences Holdings Corporation For more information visit http://www.researchandmarkets.com/research/w3...any_tissue
SNN: 33.70 (-0.35), IART: 51.49 (+0.38)
China Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include National Tissue Engineering Research Center., Integra LifeSciences and Smith & Nephew
M2 - Mon Nov 03, 6:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/23mpbz/china_tissue) has announced the addition of the "China Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "China Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the China Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, China 4 Overview of Key Companies in China, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned: - National Tissue Engineering Research Center - Integra LifeSciences Holdings Corporation - Smith & Nephew Plc - Covidien plc - BSN medical GmbH For more information visit http://www.researchandmarkets.com/research/23...ina_tissue
SNN: 33.70 (-0.35), IART: 51.49 (+0.38)
Integra LifeSciences Completes the Acquisition of MicroFrance and Xomed Manual ENT and Laparoscopy Instrumentation Lines From Medtronic
GlobeNewswire - Mon Oct 27, 5:00AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has completed the acquisition of the MicroFrance and Xomed manual ear, nose and throat (ENT) and laparoscopy instrumentation lines from Medtronic. Integra announced this acquisition on September 17, 2014.
IART: 51.49 (+0.38), MDT: 68.15 (-0.01)
Integra LifeSciences: A Buy on MicroFrance, Xomed Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 2:00PM CDT
On Oct 7, 2014, Zacks Investment Research upgraded leading medical technology developer Integra LifeSciences Holdings Corporation (IART) to a Zacks Rank #2 (Buy).
MDVN: 105.40 (-0.30), IART: 51.49 (+0.38), MDT: 68.15 (-0.01), GHDX: 35.96 (-0.38)
Integra LifeSciences to Host Its Third Quarter 2014 Earnings Results Conference Call on November 3, 2014
GlobeNewswire - Thu Oct 09, 8:37AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its third quarter 2014 financial results on Monday, November 3, 2014. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results.
IART: 51.49 (+0.38)
Global Orthopedic Trauma Fixation Devices Market Outlook 2020: DePuy Synthes Dominates with a 47% Market Share
M2 - Thu Oct 09, 2:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4qdpc9/orthopedic_trauma) has announced the addition of the "Orthopedic Trauma Fixation Devices Market - Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020" report to their offering. The global orthopedic trauma fixation devices market is witnessing significant growth due to increasing incidence of fractures and lack of substitutes. Major driving factors for the orthopedic trauma fixation devices market are increase in the elderly population, growing healthcare costs, and rising prevention measures for various orthopedic-related problems. Increasing participation in sports and rising number of road accidents are the leading causes for orthopedic trauma fracture cases. Growing demand for better facilities in orthopedic trauma surgeries, and increasing investments by governments and multinational companies has enabled the growth of the orthopedic trauma fixation devices market. On the basis of the type of fixator, internal fixators have the largest market share in the orthopedic trauma fixation devices market. On the basis of shape and size, orthopedic trauma internal fixators can be classified into intramedullary nails, intramedullary screws and plate and screw systems. For the treatment of orthopedic trauma, various types of fixators can be used, depending upon the nature and severity of the fracture. Fixator may be made of metallic or bioabsorbable material. This report forecasts future potential of orthopedic trauma fixation devices market and analyses drivers and opportunities, restraints and challenges, market trends, Porter's forces, competitive landscape and company profiles of key players. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Orthopedic Trauma Fixators - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Force Analysis Chapter 6 Market Segmentation by Type of Fixator Chapter 7 Market Segmentation by Type of Internal Fixator Chapter 8 Market Segmentation by Composition Chapter 9 Market Segmentation by Region Chapter 10 Competitive Benchmarking Chapter 11 Company Profiles - Arthrex, Inc. - B. Braun Melsungen AG - CONMED - Integra LifeSciences Holdings Corporation - Johnson & Johnson Services, Inc. - Medtronic, Inc. - Orthofix Holding Inc. - Smith & Nephew - Stryker Corporation - Tornier, Inc. - Wright Medical Technology, Inc - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/4q...dic_trauma
ZMH: 110.41 (-0.83), SNN: 33.70 (-0.35), JNJ: 107.46 (-0.32), IART: 51.49 (+0.38), MDT: 68.15 (-0.01), CNMD: 42.00 (+0.01), SYK: 86.85 (-0.68)
Integra Freedom Wrist's Commercial Availability Falls Flat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 2:10PM CDT
Initially after the news release, Integra LifeSciences' (IART) share price had risen 0.5%. However, the launch failed to sustain this positive price momentum, with shares eventually dropping 0.6% to close at $49.97 yesterday.
IART: 51.49 (+0.38), CYCC: 3.18 (-0.05), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02)
Integra to Buy Medtronic's MicroFrance, Xomed; Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:10PM CDT
Following this news, Integra's (IART) share price jumped 1.6% to eventually close at $49.76 on Friday.
CBPO: 65.00 (+4.75), IART: 51.49 (+0.38), CBM: 22.26 (+1.18), MDT: 68.15 (-0.01)
Integra Poised on Impressive Duraseal Product Line, Solid Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:50PM CDT
On Jul 3, 2014, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART).
BIIB: 321.25 (+0.17), IART: 51.49 (+0.38), COV: 92.42 (-0.02), ILMN: 194.33 (+1.75)
Integra LifeSciences Announces Full Market Release for the Integra(R) Freedom Wrist Arthroplasty System
GlobeNewswire - Thu Sep 18, 9:33AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full commercial release of the Integra(R) Freedom Wrist Arthroplasty System in the United States. The system, which is used in the treatment of wrist arthritis, has been successfully implanted in a limited release in 21 patients, during the summer months.
IART: 51.49 (+0.38)
Integra LifeSciences to Acquire Medtronic's MicroFrance and Xomed Manual ENT and Laparoscopy Instrumentation Lines
GlobeNewswire - Wed Sep 17, 5:00AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) and Medtronic, Inc. today announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60 million in cash. Integra expects the transaction to close, subject to customary closing requirements, in the fourth quarter of 2014.
IART: 51.49 (+0.38)
Integra LifeSciences Announces Changes Within Its Orthopedics and Tissue Technologies Business
GlobeNewswire - Tue Sep 02, 7:07AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has made changes to the leadership of its Orthopedics and Tissue Technologies business. The new organization enables Integra to use its resources more efficiently in order to better invest in new products and other growth initiatives. The division is now structured to maximize Integra's existing channels, build new ones and launch new products more effectively.
IART: 51.49 (+0.38)
Post Earnings Update: Integra LifeSciences Has Climbed 1.4% Higher in Past 2 Weeks (IART)
Comtex SmarTrend(R) - Mon Aug 25, 7:28AM CDT
When Integra LifeSciences (NASDAQ:IART) reported earnings 20 days ago on August 5th, 2014, analysts, on average, expected the company to report earnings of $0.63 on sales of $229.4 million. Integra LifeSciences actually reported earnings of $0.68 per share on sales of $231.4 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Integra LifeSciences have risen from $50.01 to $50.70, representing a gain of 1.4% in the past 20 days.
IART: 51.49 (+0.38)
Integra LifeSciences to Participate in the Morgan Stanley Global Healthcare Conference in September
GlobeNewswire - Thu Aug 21, 8:30AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will present at the following conferences next month:
IART: 51.49 (+0.38), MS: 34.71 (-0.24)
Integra LifeSciences Earnings In Retrospect: Down 3.0% in the Last 13 Days (IART)
Comtex SmarTrend(R) - Mon Aug 18, 10:04AM CDT
13 days ago, on August 5th, 2014, Integra LifeSciences (NASDAQ:IART) reported its earnings. Analysts, on average, expected earnings of $0.63 per share on sales of $229.4 million. Integra LifeSciences actually reported earnings of $0.68 per share on sales of $231.4 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Integra LifeSciences have fallen from $50.01 to $48.49, representing a loss of 3.0% in the past 13 days.
IART: 51.49 (+0.38)
Orthopedic Trauma Fixation Devices Market - Global Forecasts and Opportunities 2014 - 2020
M2 - Tue Aug 12, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnrmmh/orthopedic_trauma) has announced the addition of the "Orthopedic Trauma Fixation Devices Market - Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020" report to their offering. Globally, the orthopedic trauma fixation devices market is witnessing significant growth due to increasing incidence of fractures and lack of substitutes. As a result, this market is expected to grow at a CAGR of about 7.2% during 2014 - 2020. Some of the key driving factors for the orthopedic trauma fixation devices market are increase in the elderly population, growing healthcare costs, and rising prevention measures for various orthopedic-related problems. Increasing participation in sports and rising number of road accidents are the leading causes for trauma fracture cases. Growing demand for better facilities in orthopedic trauma surgeries, and increasing investments by governments and multinational companies has enabled the growth of the orthopedic trauma fixation devices market. However, the market faces some restraints such as high cost of surgery, lack of awareness, double surgeries, and absence of health insurances in developing countries. North America, including the U.S. has the largest orthopedic trauma fixation devices market. Asia is the fastest growing orthopedic trauma fixation devices market. Some of the fastest growing markets for orthopedic trauma fixation devices are China, Japan, other countries in South East Asia and the Eastern Mediterranean. On the basis of the type of fixator, internal fixators have the largest market share in the orthopedic trauma fixation devices market and are expected to grow at a CAGR of about 6.8% during 2014 - 2020. Plate and screw systems are most widely used internal fixators and the market for the same is expected to grow at a CAGR of about 7.1% during 2014 - 2020. Various orthopedic trauma fixation devices companies are increasing their focus on manufacturing of internal fixators with bioabsorbable material. Market for bioabsorbable fixators is expected to grow at a CAGR of about 8.4% during 2014 - 2020. DePuy Synthes, a Johnson & Johnson company, is a leading player in the global market for orthopedic trauma fixation, with a share of about 47.3% in 2013. Other major players of orthopedic trauma fixation devices market include Stryker Corporation, Smith & Nephew, Zimmer Holding Inc. and Orthofix Holding Inc. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Orthopedic Trauma Fixators - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Force Analysis Chapter 6 Market Segmentation by Type of Fixator Chapter 7 Market Segmentation by Type of Internal Fixator Chapter 8 Market Segmentation by Composition Chapter 9 Market Segmentation by Region Chapter 10 Competitive Benchmarking Chapter 11 Company Profiles - Arthrex, Inc. - B. Braun Melsungen AG - CONMED - Integra LifeSciences Holdings Corporation - Johnson & Johnson Services, Inc. - Medtronic, Inc. - Orthofix Holding Inc. - Smith & Nephew - Stryker Corporation - Tornier, Inc. - Wright Medical Technology, Inc - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/tn...dic_trauma
ZMH: 110.41 (-0.83), SNN: 33.70 (-0.35), JNJ: 107.46 (-0.32), IART: 51.49 (+0.38), MDT: 68.15 (-0.01), CNMD: 42.00 (+0.01), SYK: 86.85 (-0.68)
Integra LifeSciences Tops Q2 Earnings, Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 11:00AM CDT
Following the earnings release, Integra LifeSciences' (IART) share price rose 1% to eventually close at $48.60 yesterday.
CYTK: 3.70 (+0.03), CRIS: 1.29 (-0.02), IART: 51.49 (+0.38)
Integra LifeSciences Reports Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 05, 5:36AM CDT
Revenue Increased 12.6% to a Record of $231 million
IART: 51.49 (+0.38)
IART Recent Posts: http://investorshangout.com/Integra-Lifescien...ART-54399/
IART Integra Lifesciences Holdings Corp Recent Headline News
Integra LifeSciences Announces Strategic Portfolio Alignment and Plans to Create Stand-Alone Spine Business as a Separate Public Company
GlobeNewswire - Mon Nov 03, 5:28PM CST
-- Plans to Spin Off Spine Business to Create SeaSpine, a New Publicly Traded Company, By Means of Tax-Free Distribution to Integra Shareholders
IART: 51.49 (+0.38)
Integra LifeSciences Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 03, 5:28PM CST
Revenue Increased 7.7% to $229.7 Million
IART: 51.49 (+0.38)
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020
M2 - Mon Nov 03, 10:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/w3lrfq/germany_tissue) has announced the addition of the "Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. "Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the Germany Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular) and Xenograft Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, Germany 4 Overview of Key Companies in Germany, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned - Organogenesis, Inc. - Molnlycke Health Care AB - Smith & Nephew Plc - BSN medical GmbH - MedSkin Solutions Dr. Suwelack AG - Kinetic Concepts, Inc. - Covidien plc - Integra LifeSciences Holdings Corporation For more information visit http://www.researchandmarkets.com/research/w3...any_tissue
SNN: 33.70 (-0.35), IART: 51.49 (+0.38)
China Tissue Engineered - Skin Substitutes Market Outlook to 2020: Key players covered include National Tissue Engineering Research Center., Integra LifeSciences and Smith & Nephew
M2 - Mon Nov 03, 6:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/23mpbz/china_tissue) has announced the addition of the "China Tissue Engineered - Skin Substitutes Market Outlook to 2020" report to their offering. Our new report, "China Tissue Engineered - Skin Substitutes Market Outlook to 2020", provides key market data on the China Tissue Engineered - Skin Substitutes market. The report provides value, in millions of US dollars, volume (in units) and average prices (in US dollars) within market segments - Synthetic Skin Substitutes, Biosynthetic Skin Substitutes and Biologic Skin Substitutes (Allograft (Cellular and Acellular). The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Tissue Engineered - Skin Substitutes market wherever available. The data in the report is derived from dynamic market forecast models. The publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible. The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Tissue Engineered - Skin Substitutes Market, China 4 Overview of Key Companies in China, Tissue Engineered - Skin Substitutes Market 5 Appendix Companies Mentioned: - National Tissue Engineering Research Center - Integra LifeSciences Holdings Corporation - Smith & Nephew Plc - Covidien plc - BSN medical GmbH For more information visit http://www.researchandmarkets.com/research/23...ina_tissue
SNN: 33.70 (-0.35), IART: 51.49 (+0.38)
Integra LifeSciences Completes the Acquisition of MicroFrance and Xomed Manual ENT and Laparoscopy Instrumentation Lines From Medtronic
GlobeNewswire - Mon Oct 27, 5:00AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has completed the acquisition of the MicroFrance and Xomed manual ear, nose and throat (ENT) and laparoscopy instrumentation lines from Medtronic. Integra announced this acquisition on September 17, 2014.
IART: 51.49 (+0.38), MDT: 68.15 (-0.01)
Integra LifeSciences: A Buy on MicroFrance, Xomed Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 2:00PM CDT
On Oct 7, 2014, Zacks Investment Research upgraded leading medical technology developer Integra LifeSciences Holdings Corporation (IART) to a Zacks Rank #2 (Buy).
MDVN: 105.40 (-0.30), IART: 51.49 (+0.38), MDT: 68.15 (-0.01), GHDX: 35.96 (-0.38)
Integra LifeSciences to Host Its Third Quarter 2014 Earnings Results Conference Call on November 3, 2014
GlobeNewswire - Thu Oct 09, 8:37AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) will release its third quarter 2014 financial results on Monday, November 3, 2014. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results.
IART: 51.49 (+0.38)
Global Orthopedic Trauma Fixation Devices Market Outlook 2020: DePuy Synthes Dominates with a 47% Market Share
M2 - Thu Oct 09, 2:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4qdpc9/orthopedic_trauma) has announced the addition of the "Orthopedic Trauma Fixation Devices Market - Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020" report to their offering. The global orthopedic trauma fixation devices market is witnessing significant growth due to increasing incidence of fractures and lack of substitutes. Major driving factors for the orthopedic trauma fixation devices market are increase in the elderly population, growing healthcare costs, and rising prevention measures for various orthopedic-related problems. Increasing participation in sports and rising number of road accidents are the leading causes for orthopedic trauma fracture cases. Growing demand for better facilities in orthopedic trauma surgeries, and increasing investments by governments and multinational companies has enabled the growth of the orthopedic trauma fixation devices market. On the basis of the type of fixator, internal fixators have the largest market share in the orthopedic trauma fixation devices market. On the basis of shape and size, orthopedic trauma internal fixators can be classified into intramedullary nails, intramedullary screws and plate and screw systems. For the treatment of orthopedic trauma, various types of fixators can be used, depending upon the nature and severity of the fracture. Fixator may be made of metallic or bioabsorbable material. This report forecasts future potential of orthopedic trauma fixation devices market and analyses drivers and opportunities, restraints and challenges, market trends, Porter's forces, competitive landscape and company profiles of key players. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Orthopedic Trauma Fixators - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Force Analysis Chapter 6 Market Segmentation by Type of Fixator Chapter 7 Market Segmentation by Type of Internal Fixator Chapter 8 Market Segmentation by Composition Chapter 9 Market Segmentation by Region Chapter 10 Competitive Benchmarking Chapter 11 Company Profiles - Arthrex, Inc. - B. Braun Melsungen AG - CONMED - Integra LifeSciences Holdings Corporation - Johnson & Johnson Services, Inc. - Medtronic, Inc. - Orthofix Holding Inc. - Smith & Nephew - Stryker Corporation - Tornier, Inc. - Wright Medical Technology, Inc - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/4q...dic_trauma
ZMH: 110.41 (-0.83), SNN: 33.70 (-0.35), JNJ: 107.46 (-0.32), IART: 51.49 (+0.38), MDT: 68.15 (-0.01), CNMD: 42.00 (+0.01), SYK: 86.85 (-0.68)
Integra Freedom Wrist's Commercial Availability Falls Flat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 2:10PM CDT
Initially after the news release, Integra LifeSciences' (IART) share price had risen 0.5%. However, the launch failed to sustain this positive price momentum, with shares eventually dropping 0.6% to close at $49.97 yesterday.
IART: 51.49 (+0.38), CYCC: 3.18 (-0.05), CBM: 22.26 (+1.18), GILD: 109.98 (-2.02)
Integra to Buy Medtronic's MicroFrance, Xomed; Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 2:10PM CDT
Following this news, Integra's (IART) share price jumped 1.6% to eventually close at $49.76 on Friday.
CBPO: 65.00 (+4.75), IART: 51.49 (+0.38), CBM: 22.26 (+1.18), MDT: 68.15 (-0.01)
Integra Poised on Impressive Duraseal Product Line, Solid Q2 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:50PM CDT
On Jul 3, 2014, we issued an updated research report on Integra LifeSciences Holdings Corporation (IART).
BIIB: 321.25 (+0.17), IART: 51.49 (+0.38), COV: 92.42 (-0.02), ILMN: 194.33 (+1.75)
Integra LifeSciences Announces Full Market Release for the Integra(R) Freedom Wrist Arthroplasty System
GlobeNewswire - Thu Sep 18, 9:33AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full commercial release of the Integra(R) Freedom Wrist Arthroplasty System in the United States. The system, which is used in the treatment of wrist arthritis, has been successfully implanted in a limited release in 21 patients, during the summer months.
IART: 51.49 (+0.38)
Integra LifeSciences to Acquire Medtronic's MicroFrance and Xomed Manual ENT and Laparoscopy Instrumentation Lines
GlobeNewswire - Wed Sep 17, 5:00AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) and Medtronic, Inc. today announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60 million in cash. Integra expects the transaction to close, subject to customary closing requirements, in the fourth quarter of 2014.
IART: 51.49 (+0.38)
Integra LifeSciences Announces Changes Within Its Orthopedics and Tissue Technologies Business
GlobeNewswire - Tue Sep 02, 7:07AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it has made changes to the leadership of its Orthopedics and Tissue Technologies business. The new organization enables Integra to use its resources more efficiently in order to better invest in new products and other growth initiatives. The division is now structured to maximize Integra's existing channels, build new ones and launch new products more effectively.
IART: 51.49 (+0.38)
Post Earnings Update: Integra LifeSciences Has Climbed 1.4% Higher in Past 2 Weeks (IART)
Comtex SmarTrend(R) - Mon Aug 25, 7:28AM CDT
When Integra LifeSciences (NASDAQ:IART) reported earnings 20 days ago on August 5th, 2014, analysts, on average, expected the company to report earnings of $0.63 on sales of $229.4 million. Integra LifeSciences actually reported earnings of $0.68 per share on sales of $231.4 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Integra LifeSciences have risen from $50.01 to $50.70, representing a gain of 1.4% in the past 20 days.
IART: 51.49 (+0.38)
Integra LifeSciences to Participate in the Morgan Stanley Global Healthcare Conference in September
GlobeNewswire - Thu Aug 21, 8:30AM CDT
Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will present at the following conferences next month:
IART: 51.49 (+0.38), MS: 34.71 (-0.24)
Integra LifeSciences Earnings In Retrospect: Down 3.0% in the Last 13 Days (IART)
Comtex SmarTrend(R) - Mon Aug 18, 10:04AM CDT
13 days ago, on August 5th, 2014, Integra LifeSciences (NASDAQ:IART) reported its earnings. Analysts, on average, expected earnings of $0.63 per share on sales of $229.4 million. Integra LifeSciences actually reported earnings of $0.68 per share on sales of $231.4 million, beating EPS estimates by $0.05 and beating revenue estimates by $2.0 million. Since the company's report, shares of Integra LifeSciences have fallen from $50.01 to $48.49, representing a loss of 3.0% in the past 13 days.
IART: 51.49 (+0.38)
Orthopedic Trauma Fixation Devices Market - Global Forecasts and Opportunities 2014 - 2020
M2 - Tue Aug 12, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tnrmmh/orthopedic_trauma) has announced the addition of the "Orthopedic Trauma Fixation Devices Market - Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020" report to their offering. Globally, the orthopedic trauma fixation devices market is witnessing significant growth due to increasing incidence of fractures and lack of substitutes. As a result, this market is expected to grow at a CAGR of about 7.2% during 2014 - 2020. Some of the key driving factors for the orthopedic trauma fixation devices market are increase in the elderly population, growing healthcare costs, and rising prevention measures for various orthopedic-related problems. Increasing participation in sports and rising number of road accidents are the leading causes for trauma fracture cases. Growing demand for better facilities in orthopedic trauma surgeries, and increasing investments by governments and multinational companies has enabled the growth of the orthopedic trauma fixation devices market. However, the market faces some restraints such as high cost of surgery, lack of awareness, double surgeries, and absence of health insurances in developing countries. North America, including the U.S. has the largest orthopedic trauma fixation devices market. Asia is the fastest growing orthopedic trauma fixation devices market. Some of the fastest growing markets for orthopedic trauma fixation devices are China, Japan, other countries in South East Asia and the Eastern Mediterranean. On the basis of the type of fixator, internal fixators have the largest market share in the orthopedic trauma fixation devices market and are expected to grow at a CAGR of about 6.8% during 2014 - 2020. Plate and screw systems are most widely used internal fixators and the market for the same is expected to grow at a CAGR of about 7.1% during 2014 - 2020. Various orthopedic trauma fixation devices companies are increasing their focus on manufacturing of internal fixators with bioabsorbable material. Market for bioabsorbable fixators is expected to grow at a CAGR of about 8.4% during 2014 - 2020. DePuy Synthes, a Johnson & Johnson company, is a leading player in the global market for orthopedic trauma fixation, with a share of about 47.3% in 2013. Other major players of orthopedic trauma fixation devices market include Stryker Corporation, Smith & Nephew, Zimmer Holding Inc. and Orthofix Holding Inc. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Orthopedic Trauma Fixators - Industry Analysis Chapter 4 Market Trends Chapter 5 Porter's Five Force Analysis Chapter 6 Market Segmentation by Type of Fixator Chapter 7 Market Segmentation by Type of Internal Fixator Chapter 8 Market Segmentation by Composition Chapter 9 Market Segmentation by Region Chapter 10 Competitive Benchmarking Chapter 11 Company Profiles - Arthrex, Inc. - B. Braun Melsungen AG - CONMED - Integra LifeSciences Holdings Corporation - Johnson & Johnson Services, Inc. - Medtronic, Inc. - Orthofix Holding Inc. - Smith & Nephew - Stryker Corporation - Tornier, Inc. - Wright Medical Technology, Inc - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/tn...dic_trauma
ZMH: 110.41 (-0.83), SNN: 33.70 (-0.35), JNJ: 107.46 (-0.32), IART: 51.49 (+0.38), MDT: 68.15 (-0.01), CNMD: 42.00 (+0.01), SYK: 86.85 (-0.68)
Integra LifeSciences Tops Q2 Earnings, Revenues, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 07, 11:00AM CDT
Following the earnings release, Integra LifeSciences' (IART) share price rose 1% to eventually close at $48.60 yesterday.
CYTK: 3.70 (+0.03), CRIS: 1.29 (-0.02), IART: 51.49 (+0.38)
Integra LifeSciences Reports Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 05, 5:36AM CDT
Revenue Increased 12.6% to a Record of $231 million
IART: 51.49 (+0.38)
(0)
(0)Integra Lifesciences Holdings Corp. (IART) Stock Research Links
Scroll down for more posts ▼